Search Results - Sabrina Realmuto
- Showing 1 - 8 results of 8
-
1
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers by Marianna Lo Re, Marco Capobianco, Paolo Ragonese, Sabrina Realmuto, Simona Malucchi, Paola Berchialla, Giuseppe Salemi, Antonio Bertolotto
Published 2015Artigo -
2
-
3
Sleep quality in caregivers of patients with Alzheimer's disease and Parkinson's disease and its relationship to quality of life by Chiara Cupidi, Sabrina Realmuto, Gianluca Lo Coco, Antonio Cinturino, Simona Talamanca, Valentina Arnao, Valentina Perini, Marco D’Amelio, Giovanni Savettieri, Daniele Lo Coco
Published 2012Artigo -
4
Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study by Paolo Ragonese, Paolo Aridon, Giulia Vazzoler, Maria Antonietta Mazzola, Vincenzina Lo Re, Marianna Lo Re, Sabrina Realmuto, Simona Alessi, Marco D’Amelio, Giovanni Savettieri, Giuseppe Salemi
Published 2017Artigo -
5
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab by Marinella Clerico, Irene Schiavetti, Stefania Federica De Mercanti, Federico Piazza, Dario Gned, Vincenzo Brescia Morra, Roberta Lanzillo, Angelo Ghezzi, Anna Bianchi, Giuseppe Salemi, Sabrina Realmuto, Patrizia Sola, Francesca Vitetta, Paola Cavalla, Damiano Paolicelli, María Trojano, Maria Pia Sormani, Luca Durelli
Published 2014Artigo -
6
Clinical activity after fingolimod cessation: disease reactivation or rebound? by Jessica Frau, Maria Pia Sormani, Alessio Signori, Sabrina Realmuto, Damiano Baroncini, Pietro Annovazzi, Elisabetta Signoriello, Giorgia Teresa Maniscalco, Sara La Gioia, Cinzia Cordioli, Barbara Frigeni, Sarah Rasia, Giuseppe Fenu, Roberta Grasso, Arianna Sartori, Roberta Lanzillo, ML Stromillo, Silvia Rossi, Benedetta Forci, Eleonora Cocco
Published 2018Artigo -
7
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY) by Clara Grazia Chisari, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone, Paola Cavalla, Carlotta Chiavazza, Cristoforo Comi, Maura Danni, Massimo Filippi, Pietro Iaffaldano, Roberta Lanzillo, Salvatore Lo Fermo, Alessandra Lucisano, Alessandra Lugaresi, Giacomo Lus, Gerolama Alessandra Marfia, F. Marinelli, Massimiliano Mirabella, Lucia Moiola, Chiara Perin, Sabrina Realmuto, Simona Toscano, María Trojano, Domizia Vecchio, Francesco Patti
Published 2023Artigo -
8
Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience by Chiara Zecca, Francesca Bovis, Giovanni Novi, Marco Capobianco, Roberta Lanzillo, Jessica Frau, Anna Maria Repice, Bahia Hakiki, Sabrina Realmuto, Simona Bonavita, Erica Curti, Laura Brambilla, Giorgia Mataluni, Paola Cavalla, Alessia Di Sapio, Elisabetta Signoriello, Stefania Barone, Giorgia Teresa Maniscalco, Ilaria Maietta, Isabella Maraffi, Giacomo Boffa, Simona Malucchi, Agostino Nozzolillo, Giancarlo Coghe, Claudia Mechi, Giuseppe Salemi, Antonio Gallo, Rosaria Sacco, Maria Cellerino, Maria Malentacchi, Marcello De Angelis, Lorena Lorefice, Eliana Magnani, Elio Prestipino, Francesca Sperli, Vincenzo Brescia Morra, Giuseppe Fenu, Alessandro Barilaro, Gianmarco Abbadessa, Alessio Signori, Franco Granella, Maria Pia Amato, Antonio Uccelli, Claudio Gobbi, Maria Pia Sormani
Published 2019Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Multiple sclerosis
Immunology
Surgery
Psychiatry
Fingolimod
Lymphoma
Rituximab
Cohort
Discontinuation
Disease
Glatiramer acetate
Natalizumab
Neurology
Neurosurgery
Ocrelizumab
Randomized controlled trial
Adverse effect
Alemtuzumab
Anxiety
Association (psychology)
Astronomy
Azathioprine
CD20
Cardiology
Clinical endpoint
Cohort study
Computer science
Confidence interval